Rhumbline Advisers Has $112.45 Million Position in Cencora, Inc. (NYSE:COR)

Rhumbline Advisers grew its stake in Cencora, Inc. (NYSE:COR - Free Report) by 0.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 404,350 shares of the company's stock after purchasing an additional 3,282 shares during the quarter. Rhumbline Advisers owned approximately 0.21% of Cencora worth $112,446,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of COR. JFS Wealth Advisors LLC grew its position in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the last quarter. Banque Transatlantique SA bought a new stake in shares of Cencora during the 4th quarter valued at about $29,000. SBI Securities Co. Ltd. bought a new stake in shares of Cencora during the 4th quarter valued at about $30,000. Kentucky Trust Co bought a new stake in shares of Cencora during the 4th quarter valued at about $33,000. Finally, WASHINGTON TRUST Co grew its position in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

NYSE:COR traded down $1.11 during midday trading on Thursday, reaching $287.91. The stock had a trading volume of 1,190,062 shares, compared to its average volume of 1,530,520. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The firm's fifty day simple moving average is $286.06 and its 200-day simple moving average is $259.82. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock has a market capitalization of $55.80 billion, a P/E ratio of 40.95, a PEG ratio of 1.31 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the prior year, the firm earned $3.80 EPS. The business's revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on COR shares. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Robert W. Baird upped their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $274.00 to $337.00 in a research report on Tuesday. Morgan Stanley set a $288.00 target price on shares of Cencora in a research report on Tuesday, April 15th. Finally, Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $306.91.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares in the company, valued at approximately $85,680,732.63. This trade represents a 4.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. The trade was a 9.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,253 shares of company stock worth $11,102,417 in the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.